Fig. 9From: Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in SwitzerlandSensitivity analyses results – Cervical cancer incidence cases and deaths prevented with the two vaccination strategiesBack to article page